Cyclobenz review

Cyclobenz is also prescribed as Flexeril. It is commonly used to treat pain from injury, muscle spasms, and other painful musculoskeletal conditions for a short term period or two to three weeks. Cyclobenz is a muscle relaxant that also interrupts the brain's reception of pain signals sent by the nerves.


Cyclobenz is not appropriate for everyone. A thorough medical history should be assessed prior to prescribing this medication. Patients with a medical history which includes a recent heart attack, congestive heart failure, heart rhythm problems, heart block, thyroid problems, or a substance abuse problem may not be able to take Cyclobenz or may require careful monitoring while undergoing therapy with this medication, depending on the condition and the severity of the condition. This medication is not appropriate for children under 12 years of age. Patients who have taken an MAOI in the previous 14 days cannot take Cyclobenz.


The American Food and Drug Administration rated this medication as a pregnancy risk category B. This medication is not expected to cause harm or birth defects in unborn fetuses. It has yet to be determined whether or not Cyclobenz will pass into the mother's breast milk and affect a nursing baby. The prescribing physician should discuss whether the benefits outweigh the risks before prescribing this medication to a pregnant or nursing woman.


There is a risk of side effects associated with Cyclobenz, some of which are severe. A patient who is experiencing a serious side effect or an allergic reaction should seek immediate emergency medical attention. An allergic reaction will present with symptoms which include facial swelling, swelling of the lips, mouth, throat, or tongue, hives, and difficulty breathing. Other serious side effects which require emergency medical attention include symptoms such as chest pain or heaviness that involves the arm, fast heart rate, uneven heartbeat, sudden problems with vision or speech, especially when accompanied by a cephalalgia, lightheadedness, fainting, confusion, weakness, nausea, stomach pain, dark urine, clay colored stools, jaundice, convulsions, unusual thoughts or behavior, hallucinations, unusual bruising, or easy bleeding.

Other less serious side effects typically do not require emergency medical attention but should be reported to the prescribing physician. Patients are encouraged to report all side effects. Less serious side effects include symptoms such as drowsiness, dizziness, fatigue, dry mouth, costiveness, diarrhea, gas, thirst, heartburn, loss of appetite, nausea, vomiting, stomach pain, muscle weakness, sore throat, or cold symptoms. Less serious side effects can often be reduced to a tolerable level by reducing the dosage of Cyclobenz.


Cyclobenz should be taken exactly as it has been prescribed. Patients who have taken it longer than a week should not suddenly stop taking this medication. If the patient misses a dose, the dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid the potential for an overdose. The patient should never take a double dose of this medication. If an overdose is suspected, the patient should seek immediate emergency medical attention. An overdose will present with symptoms which include chest pain, tremors, drowsiness, fast heart beat, slurred speech, hallucinations, confusion, nausea, vomiting, or seizures.


There is a risk of negative medication interactions associated with Cyclobenz. A thorough medical history should be understood prior to prescribing this medication. Patients should inquire with the prescribing physician before taking any new medicaments, including over the counter medicaments. Patients who have taken an MAOI within the previous 14 days may experience spirit threatening interactions when taken with Cyclobenz. Other interactions include antidepressants, narcotic pain relievers, muscle relaxants, sedatives, and phenothiazines.

Cyclobenz has the following structural formula:

Chemical structure of cyclobenz

 Molecular formula of cyclobenz is C20H21N
 Chemical IUPAC Name is 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
 Molecular weight is 275.387 g/mol
 Cyclobenz available : 5mg tablets, 10mg tablets

Generic name: Cyclobenzaprine

Brand name(s): Flexeril, Flexiban, Proeptatriene, Proheptatriene

  Your Cyclobenz review